top of page

MENU

  • AutorenbildJuergen Mairhofer

-exPAND protein labeling collaboration unites enGenes with ACIB

Vienna, Austria: – Recombinant protein specialist manufacturer enGenes Biotech GmbH (enGenes) has announced the formation of the -eXPAND collaboration with ACIB GmbH to develop site-specific incorporation of non-native amino acids into proteins.

The new technology will be based on the enGenes-eXpress platform for growth-decoupled protein production in Escherichia coli (E.coli), with expansion of the genetic code.

The Austrian Research Promotion agency (FFG) will fund the eXPAND project as a BRIDGE 1 project, to close the “funding gap” between basic and applied research.

Cutting edge technology

“We are very excited about this new project, which underlines that enGenes Biotech is working on the cutting edge of industry relevant innovation,” commented enGenes CEO Dr. Juergen Mairhofer.

“Site-specific labelling is currently very inefficient and alternative approaches are leading to product heterogeneity. Our new approach will be more cost effective with higher labelling efficiencies to promote site specific labeling or conjugation of payload that is so relevant to antibody fragment drug conjugates, for example,” added Dr. Birgit Wiltschi, ACIB’s Junior Group Leader Synthetic Biology, ACIB GmbH.

Comments


bottom of page